Skip to main content
. 2017 Dec 18;15(3):3287–3294. doi: 10.3892/ol.2017.7633

Figure 2.

Figure 2.

Hypermethylation of DACT2 promoter majorly contributes to the loss of DACT2 in human breast cancer. (A) MSP was used to assess the methylation status of DACT2 promoter in breast cancer tissues. (B) Detection of the DACT2 mRNA in 3 well-established breast cancer cell lines. (C) Detection of the DACT2 protein in 3 well-established breast cancer cell lines. (D) MSP was performed to assess the methylation status of DACT2 promoter in MDA-MB-468 cells. (E) 5-Aza induces the re-expression of DACT2 expression in MDA-MB-468 cells. DACT2, dishevelled-associated antagonist of β-catenin homolog 2; MSP, methylation-specific polymerase chain reaction; IVD, in vitro methylated DNA; NL, normal lymphocyte DNA; U, unmethylated; M, methylated; GAPDH, glyceraldehyde 3-phosphate dehydrogenase; 5-Aza, 5-azacytidene; ctrl, control.